Version 1
: Received: 27 May 2019 / Approved: 28 May 2019 / Online: 28 May 2019 (10:05:26 CEST)
How to cite:
Woods, D.; Jiang, Q.; Chu, X. Monoclonal Antibody as an Emerging Therapies for Ischemic Stroke. Preprints2019, 2019050326. https://doi.org/10.20944/preprints201905.0326.v1
Woods, D.; Jiang, Q.; Chu, X. Monoclonal Antibody as an Emerging Therapies for Ischemic Stroke. Preprints 2019, 2019050326. https://doi.org/10.20944/preprints201905.0326.v1
Woods, D.; Jiang, Q.; Chu, X. Monoclonal Antibody as an Emerging Therapies for Ischemic Stroke. Preprints2019, 2019050326. https://doi.org/10.20944/preprints201905.0326.v1
APA Style
Woods, D., Jiang, Q., & Chu, X. (2019). Monoclonal Antibody as an Emerging Therapies for Ischemic Stroke. Preprints. https://doi.org/10.20944/preprints201905.0326.v1
Chicago/Turabian Style
Woods, D., Qian Jiang and Xiang-Ping Chu. 2019 "Monoclonal Antibody as an Emerging Therapies for Ischemic Stroke" Preprints. https://doi.org/10.20944/preprints201905.0326.v1
Abstract
Acute ischemic strokes are the third leading cause of death and the leading cause of neurological disability worldwide. The oxygen and glucose deprivation associated with ischemic strokes not only leads to neuronal cell death, but also increases the inflammatory response and decreases functional output of the brain. The only intervention approved by US Federal Drug and Food Administration for treatment of ischemic strokes is tissue plasminogen activator (tPA), however, such treatment can only be given within 4.5 hours of the onset of stroke-like symptoms. This narrow time-range limits its application, and it also might induce detrimental rather than beneficial effects to stroke patients by treatment of the tPA. In order to reduce the infarct volume of an acute ischemic stroke while increasing the time period for treatment, emerging therapies reveal great potential by targeting inflammation, growth factors, ion channels, and neurotransmitter receptors with monoclonal antibody (MAB). With successfully application in the treatment of cancer patient by MAB, in this review, we will focus on recent advances on stroke therapy by using MAB on the treatment of stroke by targeting inflammation, growth factors, ion channels, and neurotransmitter receptors. Therefore, developing specific MAB targeting the signaling pathway of stroke will contribute to stroke therapy.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
